Johnson & Johnson Climbs to Fresh Highs as Valuation Debate Heats Up
Johnson & Johnson has surged to $275.66 after delivering a 59.3% total return over the past year, powered by FDA clearances, new drug approvals and revenue growth. Street targets are split, with a bull case at $320 and InvestingPro’s Fair Value model implying nearly 10% downside. The stock’s forward multiples reflect hopes for robust oncology-led e…